3/10/25 16:09 | 3/7/25 | BIIB | Health | BioPrd | Biological Products, (No Diag | Sherwin Stephen A | MA | D | | 1 | S | -1,314 | 150.02 | 0 | -9 | | 11 | D | | | | | | | | | | | | | | |
2/12/25 17:48 | 2/10/25 | BIIB | Health | BioPrd | Biological Products, (No Diag | Singhal Priya | MA | O | Head of | 3 | M.d | 0 | 0.00 | 0 | 5 | 138 | 9 | D | | | | | | | | | | | | | | |
2/12/25 17:47 | 2/10/25 | BIIB | Health | BioPrd | Biological Products, (No Diag | Murphy Nicole | MA | O | Head of | 2 | M.d | 0 | 0.00 | 0 | 6 | 82 | 14 | D | | | | | | | | | | | | | | |
2/12/25 17:46 | 2/10/25 | BIIB | Health | BioPrd | Biological Products, (No Diag | McDonnell Michael R | MA | O | EVP,CFO | 2 | M.d | 0 | 0.00 | 0 | 8 | 47 | 24 | D | | | | | | | | | | | | | | |
2/12/25 17:44 | 2/10/25 | BIIB | Health | BioPrd | Biological Products, (No Diag | Kramer Robin | MA | O | Chief Ac | 2 | M.d | 0 | 0.00 | 0 | 2 | 41 | 8 | D | | | | | | | | | | | | | | |
2/12/25 17:43 | 2/10/25 | BIIB | Health | BioPrd | Biological Products, (No Diag | Gregory Ginger | MA | O | EVP,HR | 2 | M.d | 0 | 0.00 | 0 | 6 | 47 | 18 | D | | | | | | | | | | | | | | |
2/12/25 17:42 | 2/10/25 | BIIB | Health | BioPrd | Biological Products, (No Diag | Alexander Susan H | MA | O | EVP GC | 2 | M.d | 0 | 0.00 | 0 | 7 | 14 | 56 | D | | | | | | | | | | | | | | |
2/12/25 17:40 | 2/10/25 | BIIB | Health | BioPrd | Biological Products, (No Diag | Izzar Rachid | MA | O | Head of | 2 | M.d | 0 | 0.00 | 0 | 5 | 168 | 9 | D | | | | | | | | | | | | | | |
2/10/25 18:55 | 2/7/25 | BIIB | Health | BioPrd | Biological Products, (No Diag | Viehbacher Christopher | MA | DO | P,CEO | 1 | M.d | 0 | 0.00 | 0 | 9 | 237 | 13 | D | | | | | | | | | | | | | | |
2/10/25 18:52 | 2/7/25 | BIIB | Health | BioPrd | Biological Products, (No Diag | Grogan Jane | MA | O | Head of | 1 | M.d | 0 | 0.00 | 0 | 1 | 999% | 1 | D | | | | | | | | | | | | | | |
2/10/25 18:51 | 2/7/25 | BIIB | Health | BioPrd | Biological Products, (No Diag | Keeney Adam | MA | O | Head of | 1 | M.d | 0 | 0.00 | 0 | 2 | 999% | 2 | D | | | | | | | | | | | | | | |